Hagop Kantarjian/ mdanderson.org
Sep 1, 2023, 18:38
Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.
Hagop Kantarjian, at MD Anderson Cancer Center, shared on Twitter:
“Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML. With a median F/U of 76 months, CR/CRi Overall was 83% (74% MRD neg) & 4-yr OS of 57%; Among FLT3-ITD, CR/CRi was 95% (81% MRD neg), w/ 5-yr OS of 59%.”
For the article click here.
Source: Hagop Kantarjian/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29